Qepler | summits & conferences | 3rd Annual Genotoxic Impurities in Pharmaceuticals Virtual Summit, 9-10 March 2023, VIRTUAL
Event Location:
Online Conference
09 - 10 March 2023
Contact Person: Evgenia Makar
Contact Person: Evgenia Makar, Qepler s.r.o.
Contact Person: Denis Polikarpov
Contact Person: Denis Polikarpov, Qepler s.r.o.

Conference Overview

For the transformation of starting material into the product is needed API synthesis, which involves multiple reaction steps, including reagents, intermediates, catalysts, solvents and others. As a result, low levels of by-products may appear in API as impurities. This impurity may have toxicity, incl. carcinogenicity and genotoxicity, what may cause mutations, potentially leading to cancer. Due to this fact and focusing on ensuring safety of public health is critical to identify, monitor, analyse and control genotoxic impurities and strive to their minimum level. This has led to the crucial need in the development and improvement of analytical methods.

The Genotoxic Impurities in Pharmaceuticals Summit 2023 is focusing on overcoming challenges and barriers, sharing knowledge, strategies, best techniques and new methodologies in GTI predictions, analysis and control during the drug development process, overview and practical implementation of GTI guidelines and regulations (ICH M7 and ICH Q3D), risk assessment, exposure limits calculation and predictions' empowerment through in silico.

The featured talks on:

  • Analytical approaches to cover potentially harmful Impurities in drug formulations
  • Exploring the scale of potential nitrosamine risk associated with existing approved APIs
  • Development of a drug product workflow for nitrosamine risk assessments?
  • Quantitative analysis of in vivo mutagenicity dose-response data for risk assessment and regulatory decision-making: a case study of alkylnitrosamines.
  • Technologies for Optimising Performance, Minimising Risk and preparing for the Future in Trace Impurity Quantification
  • Setting Limits for Complex Nitrosamines (NDSRIs)
  • Incorporating Nitrosamine Risk Mitigation Activities Across a Diverse Development Portfolio
  • Inhibition of Nitrosamine Formation in Drug Products
  • Impact of different rat or hamster S9 fractions on the metabolic activation of low-molecular-weight N-nitrosamines – a comparative analysis
  • Analytical testing and control approaches for GTIs in drug substance
  • Case Studies of Nitrosamines in Pharmaceuticals
  • Recent updates on Nitrosamine Impurities by EMA & FDA
  • Enhancing nitrosamines analysis: a focus on complex nitrosamines (NDSRIs or NO-APIs)
  • How Sanofi scientists streamlined their in silico hazard assessment of potential genotoxic impurities by collaborating with Discngine
  • Development of in silico systems for expert review under ICH M7 guideline: increasing efficiency through automated arguments
  • Expert Review of In Silico Mutagenicity Predictions
  • Analytical Strategies for Enhancing Selectivity and Sensitivity of Genotoxic Impurities
  • A review of ongoing efforts to optimize the Ames assay by the HESI-GTTC Nitrosamine Mechanismbased Genotoxicity Risk Assessment (NA-MGRA) Subgroup
  • Applications of computational methods in the assessment of extractables and leachables

Meet our Speakers

Our Partners



Abbott Healthcare Products B.V. - Alkaloid AD - Angelini - Astellas Pharma Europe BV - AstraZeneca - Bayer AG - Bristol-Myers Squibb - Charles River Laboratories - Cipla Limited - Elanco Animal Health - Elpen Pharmaceutical Co.Inc. - Eurofarma labs - F. Hoffmann-La Roche Ltd - Fresenius Kabi Deutschland GmbH - GlaxoSmithKline - Intertek (Schweiz) AG - Lhasa Limited - Merck & Co., Inc. - Nelson Labs Europe - S-IN Soluzioni Informatiche Srl - SCIEX - Smithers Rapra Ltd. - Teva - Teva Pharmaceutical Industries Ltd. - ToxMinds BVBA - UCB Biopharma sprl. - Others

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookies Policy.